AU2013219945B2 - Culturing of mesenchymal stem cells - Google Patents

Culturing of mesenchymal stem cells Download PDF

Info

Publication number: AU2013219945B2
Authority: AU; Australia
Prior art keywords: cells; nicotinamide; mesenchymal stem; fgf4; stem cells
Prior art date: 2012-02-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2013219945A

Other languages

English (en)

Other versions

AU2013219945A1 (en

Inventor

Tony Peled

Yair STEINHARDT

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gamida Cell Ltd

Original Assignee

Gamida Cell Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-13

Filing date

2013-02-13

Publication date

2017-12-07

2013-02-13 Application filed by Gamida Cell Ltd filed Critical Gamida Cell Ltd

2014-08-28 Publication of AU2013219945A1 publication Critical patent/AU2013219945A1/en

2017-12-07 Application granted granted Critical

2017-12-07 Publication of AU2013219945B2 publication Critical patent/AU2013219945B2/en

Status Ceased legal-status Critical Current

2033-02-13 Anticipated expiration legal-status Critical

Links

210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 332
238000012258 culturing Methods 0.000 title claims abstract description 88
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 669
235000005152 nicotinamide Nutrition 0.000 claims abstract description 336
239000011570 nicotinamide Substances 0.000 claims abstract description 334
229960003966 nicotinamide Drugs 0.000 claims abstract description 334
108090000381 Fibroblast growth factor 4 Proteins 0.000 claims abstract description 184
238000000034 method Methods 0.000 claims abstract description 125
102000003969 Fibroblast growth factor 4 Human genes 0.000 claims abstract 7
210000004027 cell Anatomy 0.000 claims description 390
102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 178
230000004069 differentiation Effects 0.000 claims description 46
239000003102 growth factor Substances 0.000 claims description 41
210000001185 bone marrow Anatomy 0.000 claims description 34
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
238000002054 transplantation Methods 0.000 claims description 25
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 21
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 21
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 18
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 18
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 17
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 17
239000011575 calcium Substances 0.000 claims description 17
229910052791 calcium Inorganic materials 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 16
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 14
210000000988 bone and bone Anatomy 0.000 claims description 14
238000004113 cell culture Methods 0.000 claims description 14
208000035475 disorder Diseases 0.000 claims description 14
210000000577 adipose tissue Anatomy 0.000 claims description 13
101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 12
101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 9
102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 9
230000029663 wound healing Effects 0.000 claims description 8
102100032912 CD44 antigen Human genes 0.000 claims description 7
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 7
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
210000003743 erythrocyte Anatomy 0.000 claims description 5
208000015122 neurodegenerative disease Diseases 0.000 claims description 5
230000017423 tissue regeneration Effects 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 4
208000015100 cartilage disease Diseases 0.000 claims description 4
230000004770 neurodegeneration Effects 0.000 claims description 4
108091033319 polynucleotide Proteins 0.000 claims description 4
102000040430 polynucleotide Human genes 0.000 claims description 4
239000002157 polynucleotide Substances 0.000 claims description 4
208000020084 Bone disease Diseases 0.000 claims description 3
208000020446 Cardiac disease Diseases 0.000 claims description 3
208000028389 Nerve injury Diseases 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
208000019622 heart disease Diseases 0.000 claims description 3
208000019423 liver disease Diseases 0.000 claims description 3
230000008764 nerve damage Effects 0.000 claims description 3
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
229940126864 fibroblast growth factor Drugs 0.000 claims 1
210000004271 bone marrow stromal cell Anatomy 0.000 abstract 1
239000002609 medium Substances 0.000 description 91
230000000694 effects Effects 0.000 description 69
210000003958 hematopoietic stem cell Anatomy 0.000 description 33
230000035755 proliferation Effects 0.000 description 29
239000012091 fetal bovine serum Substances 0.000 description 25
238000001943 fluorescence-activated cell sorting Methods 0.000 description 25
210000001519 tissue Anatomy 0.000 description 24
108010081589 Becaplermin Proteins 0.000 description 23
108091003079 Bovine Serum Albumin Proteins 0.000 description 23
210000000130 stem cell Anatomy 0.000 description 23
108010004729 Phycoerythrin Proteins 0.000 description 17
238000000338 in vitro Methods 0.000 description 17
238000011282 treatment Methods 0.000 description 16
239000004033 plastic Substances 0.000 description 15
229920003023 plastic Polymers 0.000 description 15
230000001464 adherent effect Effects 0.000 description 14
230000001965 increasing effect Effects 0.000 description 14
102100037241 Endoglin Human genes 0.000 description 13
239000000203 mixture Substances 0.000 description 13
102000004889 Interleukin-6 Human genes 0.000 description 12
108090001005 Interleukin-6 Proteins 0.000 description 12
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 11
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 11
230000010261 cell growth Effects 0.000 description 11
239000001963 growth medium Substances 0.000 description 11
239000000463 material Substances 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
238000003556 assay Methods 0.000 description 10
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 10
239000003550 marker Substances 0.000 description 10
238000005259 measurement Methods 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
230000002195 synergetic effect Effects 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
-1 SH2) Proteins 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 9
230000028327 secretion Effects 0.000 description 9
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
238000002965 ELISA Methods 0.000 description 8
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 8
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 8
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 8
102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 8
102000004142 Trypsin Human genes 0.000 description 8
108090000631 Trypsin Proteins 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000003814 drug Substances 0.000 description 8
238000005538 encapsulation Methods 0.000 description 8
150000005480 nicotinamides Chemical class 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
239000012588 trypsin Substances 0.000 description 8
101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 7
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 7
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
230000004663 cell proliferation Effects 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
210000005087 mononuclear cell Anatomy 0.000 description 7
238000010899 nucleation Methods 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
210000002826 placenta Anatomy 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
238000011579 SCID mouse model Methods 0.000 description 6
102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
230000000735 allogeneic effect Effects 0.000 description 6
230000024245 cell differentiation Effects 0.000 description 6
239000003636 conditioned culture medium Substances 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
210000004700 fetal blood Anatomy 0.000 description 6
230000003394 haemopoietic effect Effects 0.000 description 6
230000001976 improved effect Effects 0.000 description 6
238000002955 isolation Methods 0.000 description 6
210000002510 keratinocyte Anatomy 0.000 description 6
238000007898 magnetic cell sorting Methods 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000003094 microcapsule Substances 0.000 description 6
230000009758 senescence Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
210000003954 umbilical cord Anatomy 0.000 description 6
229920001917 Ficoll Polymers 0.000 description 5
229930182566 Gentamicin Natural products 0.000 description 5
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
208000009329 Graft vs Host Disease Diseases 0.000 description 5
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 5
101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 5
229930182816 L-glutamine Natural products 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 5
102100040120 Prominin-1 Human genes 0.000 description 5
230000003110 anti-inflammatory effect Effects 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
239000000969 carrier Substances 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
229960002518 gentamicin Drugs 0.000 description 5
208000024908 graft versus host disease Diseases 0.000 description 5
210000005260 human cell Anatomy 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
238000013508 migration Methods 0.000 description 5
230000005012 migration Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000002062 proliferating effect Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000013589 supplement Substances 0.000 description 5
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
102400001368 Epidermal growth factor Human genes 0.000 description 4
101800003838 Epidermal growth factor Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 4
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
102000013814 Wnt Human genes 0.000 description 4
108050003627 Wnt Proteins 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
230000009815 adipogenic differentiation Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000000845 cartilage Anatomy 0.000 description 4
239000002771 cell marker Substances 0.000 description 4
238000002659 cell therapy Methods 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
239000000306 component Substances 0.000 description 4
210000002808 connective tissue Anatomy 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
229940116977 epidermal growth factor Drugs 0.000 description 4
238000009472 formulation Methods 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000002372 labelling Methods 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
AGJBKFAPBKOEGA-UHFFFAOYSA-M 2-methoxyethylmercury(1+);acetate Chemical compound COCC[Hg]OC(C)=O AGJBKFAPBKOEGA-UHFFFAOYSA-M 0.000 description 3
102100022464 5'-nucleotidase Human genes 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010047620 Phytohemagglutinins Proteins 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
101150052863 THY1 gene Proteins 0.000 description 3
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
230000002293 adipogenic effect Effects 0.000 description 3
210000002798 bone marrow cell Anatomy 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000011109 contamination Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229960003512 nicotinic acid Drugs 0.000 description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
230000009818 osteogenic differentiation Effects 0.000 description 3
230000001885 phytohemagglutinin Effects 0.000 description 3
238000007747 plating Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
230000001172 regenerating effect Effects 0.000 description 3
230000011664 signaling Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 2
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
101710145634 Antigen 1 Proteins 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
102100024210 CD166 antigen Human genes 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
102100035716 Glycophorin-A Human genes 0.000 description 2
108091005250 Glycophorins Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000003964 Histone deacetylase Human genes 0.000 description 2
108090000353 Histone deacetylase Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
101000958041 Homo sapiens Musculin Proteins 0.000 description 2
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
229920001612 Hydroxyethyl starch Polymers 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102100022338 Integrin alpha-M Human genes 0.000 description 2
102100025304 Integrin beta-1 Human genes 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
102100039564 Leukosialin Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
208000019022 Mood disease Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
BAWFJGJZGIEFAR-NNYOXOHSSA-M NAD(1-) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-M 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
208000037919 acquired disease Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
238000011316 allogeneic transplantation Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
230000009816 chondrogenic differentiation Effects 0.000 description 2
230000002648 chondrogenic effect Effects 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
102000046949 human MSC Human genes 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000012533 medium component Substances 0.000 description 2
239000011325 microbead Substances 0.000 description 2
238000010232 migration assay Methods 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
230000000921 morphogenic effect Effects 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000008399 tap water Substances 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
UBDXZYYYWGIRGN-UHFFFAOYSA-N 2-cyano-5-phenylpenta-2,4-dienoic acid Chemical compound OC(=O)C(C#N)=CC=CC1=CC=CC=C1 UBDXZYYYWGIRGN-UHFFFAOYSA-N 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
PQQIIAHYPFFGDK-UHFFFAOYSA-N 4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one;3h-1,3-oxazol-2-one Chemical compound O=C1NC=CO1.O1C(=O)C(=COCC)N=C1C1=CC=CC=C1 PQQIIAHYPFFGDK-UHFFFAOYSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
102000004008 5'-Nucleotidase Human genes 0.000 description 1
NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
208000017194 Affective disease Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000030016 Avascular necrosis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000009410 Chemokine receptor Human genes 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
241000630627 Diodella Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010036395 Endoglin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
102100025323 Integrin alpha-1 Human genes 0.000 description 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
101710177504 Kit ligand Proteins 0.000 description 1
MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
238000011789 NOD SCID mouse Methods 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
206010029825 Nucleated red cells Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
206010034576 Peripheral ischaemia Diseases 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102000011990 Sirtuin Human genes 0.000 description 1
108050002485 Sirtuin Proteins 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
208000027520 Somatoform disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
108010017842 Telomerase Proteins 0.000 description 1
101710113649 Thyroid peroxidase Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
206010048873 Traumatic arthritis Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
229930003537 Vitamin B3 Natural products 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
108010076089 accutase Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
239000013566 allergen Substances 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000003321 amplification Effects 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000010923 batch production Methods 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000032341 cell morphogenesis Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006757 chemical reactions by type Methods 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
201000005043 chondromalacia Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011281 clinical therapy Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000003021 clonogenic effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000487 effect on differentiation Effects 0.000 description 1
230000002884 effect on inflammation Effects 0.000 description 1
230000000431 effect on proliferation Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000005206 flow analysis Methods 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002343 gold Chemical class 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229940027278 hetastarch Drugs 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
102000057231 human FGF4 Human genes 0.000 description 1
102000057239 human FGF7 Human genes 0.000 description 1
102000044916 human PTPRC Human genes 0.000 description 1
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
229960004171 hydroxychloroquine Drugs 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008102 immune modulation Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000007443 liposuction Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
229940072082 magnesium salicylate Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
229940013798 meclofenamate Drugs 0.000 description 1
210000003716 mesoderm Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
108091070501 miRNA Proteins 0.000 description 1
239000002679 microRNA Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
HFZXBZIYMINYKS-UHFFFAOYSA-N n-sulfanylpyridine-3-carboxamide Chemical compound SNC(=O)C1=CC=CN=C1 HFZXBZIYMINYKS-UHFFFAOYSA-N 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000004031 neuronal differentiation Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
230000007959 normoxia Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
210000004663 osteoprogenitor cell Anatomy 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000002688 persistence Effects 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
229920000083 poly(allylamine) Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
108010043671 prostatic acid phosphatase Proteins 0.000 description 1
238000012514 protein characterization Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
XQWBMZWDJAZPPX-UHFFFAOYSA-N pyridine-3-carbothioamide Chemical class NC(=S)C1=CC=CN=C1 XQWBMZWDJAZPPX-UHFFFAOYSA-N 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
229960000953 salsalate Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
108010053226 substrate adhesion molecules Proteins 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
229960004380 tramadol Drugs 0.000 description 1
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
238000001665 trituration Methods 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000019160 vitamin B3 Nutrition 0.000 description 1
239000011708 vitamin B3 Substances 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Developmental Biology & Embryology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)

AU2013219945A 2012-02-13 2013-02-13 Culturing of mesenchymal stem cells Ceased AU2013219945B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261597899P	2012-02-13	2012-02-13
US201261597909P	2012-02-13	2012-02-13
US61/597,909		2012-02-13
US61/597,899		2012-02-13
PCT/IL2013/050136 WO2013121426A1 (en)	2012-02-13	2013-02-13	Culturing of mesenchymal stem cells

Publications (2)

Publication Number	Publication Date
AU2013219945A1 AU2013219945A1 (en)	2014-08-28
AU2013219945B2 true AU2013219945B2 (en)	2017-12-07

Family

ID=47953447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2013219945A Ceased AU2013219945B2 (en)	2012-02-13	2013-02-13	Culturing of mesenchymal stem cells

Country Status (12)

Country	Link
US (2)	US10047345B2 (de)
EP (2)	EP2814951B1 (de)
JP (2)	JP6348848B2 (de)
CN (2)	CN104204193B (de)
AU (1)	AU2013219945B2 (de)
BR (1)	BR112014020119A2 (de)
CA (1)	CA2863795A1 (de)
HK (1)	HK1202581A1 (de)
IL (1)	IL234095B (de)
IN (1)	IN2014MN01680A (de)
SG (1)	SG11201404608WA (de)
WO (2)	WO2013121427A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
KR102002090B1 (ko) *	2011-06-03	2019-07-19	메소블라스트, 아이엔씨.	신경성 질환을 치료 또는 예방하는 방법들
JP6607675B2 (ja)	2011-07-06	2019-11-20	セルセラピーリミテッド	中胚葉系列の前駆細胞
EP2814951B1 (de)	2012-02-13	2019-04-03	Gamida-Cell Ltd.	Kultivierung mesenchymaler stammzellen
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
KR101583569B1 (ko) *	2013-05-15	2016-01-08	라정찬	정맥 투여용 줄기세포 조성물
KR101548956B1 (ko)	2013-09-05	2015-09-01	메디포스트(주)	세포 크기에 따른 간엽줄기세포 배양방법
JP6765961B2 (ja) *	2013-11-04	2020-10-07	ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ，ＤｉｃｋｉｎｓｏｎＡｎｄＣｏｍｐａｎｙ	多能性間質細胞集団の免疫調節ポテンシャル
AU2015243236B2 (en) *	2014-04-11	2020-12-03	The Administrators Of The Tulane Educational Fund	Cell-surface marker of early MSC aging
WO2015191545A1 (en) *	2014-06-09	2015-12-17	University Of Washington	Methods of protection against ischemia reperfusion injury
US10493105B2 (en) *	2014-09-11	2019-12-03	Taiwan Mitochondrion Applied Technology Co., Ltd	Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease
CN105748514A (zh) *	2015-01-05	2016-07-13	洪士杰	用于治疗肝脏疾病的间叶干细胞
CN108138137A (zh)	2015-08-12	2018-06-08	车比奥泰有限公司	增强的脐带来源的粘着干细胞、其制备方法及其用途
WO2017087505A1 (en) *	2015-11-17	2017-05-26	The Regents Of The University Of Michigan	Macromolecular structures and uses thereof
US10894947B1 (en) *	2016-04-29	2021-01-19	Hope Biosciences, Llc	Method for generating protein rich conditioned medium
US10959425B2 (en)	2016-04-29	2021-03-30	Hope Biosciences, Llc	Method of banking stem cells
US11111480B2 (en)	2016-04-29	2021-09-07	Hope Biosctences, Llc	Culture media for multipotent stem cells
US10513689B2 (en)	2016-04-29	2019-12-24	Hope Biosciences, Llc	Culture media for multipotent stem cells
US11684574B2 (en)	2016-06-30	2023-06-27	University of Pittsburgh—of the Commonwealth System of Higher Education	Artificial cells and delivery devices for use in tissue engineering, and related methods
CN106701671A (zh) *	2016-11-14	2017-05-24	天津市康婷生物工程有限公司	一种利于间充质干细胞应用于骨再生的培养体系
US20200085881A1 (en) *	2016-12-16	2020-03-19	Osaka Air Machine Service, Ltd.	Tissue healing agent
CN106520691A (zh) *	2016-12-30	2017-03-22	潍坊医学院	一种皮肤间充质干细胞的分离及培养方法
WO2018130554A1 (en) *	2017-01-11	2018-07-19	Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung	Mesenchymal stem cell-derived extracellular vesicles and their medical use
US11634690B2 (en)	2017-01-31	2023-04-25	Oriental Yeast Co., Ltd.	Agent for accelerating growth of pluripotent stem cells
EP3623466A4 (de) *	2017-05-12	2020-08-12	FUJIFILM Corporation	Verfahren zur herstellung mesenchymaler stammzellen und anwendung davon
CN107083357B (zh) *	2017-06-16	2021-04-02	四川农业大学	一种诱导培养骨髓间充质干细胞的方法
CL2017002357A1 (es) *	2017-09-16	2018-04-20	Cells For Cells S A	Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
EP3697894A1 (de) *	2017-10-20	2020-08-26	Bone Therapeutics S.A.	Verfahren zur unterscheidung mesenchymaler stammzellen
CN108220231A (zh) *	2018-01-23	2018-06-29	广州资生生物科技有限公司	一种干细胞培养基及其制备方法和应用
CN108220161B (zh) *	2018-01-24	2022-06-14	北京臻溪谷医学研究中心（有限合伙）	一种多细胞制备实验室布局方案
JP7287948B2 (ja)	2018-03-22	2023-06-06	オリエンタル酵母工業株式会社	多分化能性幹細胞分化促進剤
KR102337954B1 (ko) *	2018-08-16	2021-12-10	차의과학대학교 산학협력단	뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
TW202045716A (zh) *	2019-02-28	2020-12-16	澳大利亞商辛那塔治療有限公司	用於改善間葉幹細胞之血管生成潛力的方法
CN109810943A (zh) *	2019-03-21	2019-05-28	河南科技大学	一种猪肌源性间充质干细胞分离培养基及分离培养方法
US10881693B2 (en)	2019-04-09	2021-01-05	Combangio, Inc.	Processes for making and using a mesenchymal stem cell derived secretome
KR102323056B1 (ko) *	2019-05-02	2021-11-09	에스씨엠생명과학 주식회사	hPL 함유 배지에서 배양된 중간엽 줄기세포의 배양액을 포함하는 화장료 조성물
US20200407691A1 (en) *	2019-06-27	2020-12-31	University Of South Carolina	Methods and Materials for Modulation of Cell Secretome Production and Composition
US20230210747A1 (en) *	2020-02-26	2023-07-06	Reelabs Pvt. Ltd.	Anti-Ageing Cosmetic Compositions for Men and Women, Containing Bioactive Protein, and the Method of its Production
EP4132546A4 (de)	2020-04-07	2024-05-01	Combangio, Inc.	Aus lyophilisierten mesenchymalen stammzellen abgeleitetes sekretom und verwendungen davon
CN111518865B (zh) *	2020-05-29	2023-10-03	湖州中科朗斯生物技术有限公司	一种基于间充质干细胞的皮肤修复活性成分的筛选方法
CN112116555B (zh) *	2020-08-12	2024-03-26	清华大学深圳国际研究生院	间充质干细胞的生理功能的检测方法及其应用
KR102435452B1 (ko) *	2020-11-11	2022-09-07	이엔셀 주식회사	노화가 감소되고 줄기세포능이 보존된 초기 중간엽 줄기세포, 및 그 배양방법
CN112516169A (zh) *	2020-12-17	2021-03-19	陕西佰傲干细胞再生医学有限公司	一种用于治疗肠炎的间充质干细胞及其制备方法
CA3135658A1 (en) *	2020-12-24	2022-06-24	Riam Shammaa	Mesenchymal stem cells for treatment of skin disorders and skin problems
CN113249315A (zh) *	2021-05-31	2021-08-13	上海南滨江细胞生物科技有限公司	一种脐血含有间充质干细胞的培养方法
WO2023158710A1 (en) *	2022-02-17	2023-08-24	MAM Holdings of West Florida, L.L.C.	Derived multiple allogeneic proteins paracrine signaling (d-mapps) regenerative biologics platform technology adjuvant therapy for the prevention and targeted treatment of cancer and other disorders
CN114703133B (zh) *	2022-05-10	2023-09-19	苏州依科赛生物科技股份有限公司	一种干细胞专用胎牛血清的筛选工艺
CN115305234B (zh) *	2022-09-28	2023-01-17	呈诺再生医学科技(北京)有限公司	一种制备间充质干细胞的方法、间充质干细胞和应用
WO2024120329A1 (zh) *	2022-12-06	2024-06-13	苏州血霁生物科技有限公司	一种分化血小板的方法、培养基及应用
CN119060948B (zh) *	2024-10-16	2025-06-13	广州赛基特生物科技有限公司	一种间充质干细胞培养扩增培养基及其制备方法
CN119405783A (zh) *	2025-01-08	2025-02-11	奥辰生物(云南)有限公司	一种包含高活性脐带msc的药物组合物

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US3715345A (en)	1970-08-03	1973-02-06	Lilly Co Eli	Glucagon separation process
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl)	1970-12-28	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en)	1971-06-21	1975-08-26	Biological Developments	Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en)	1971-09-01	1974-12-10	W Dreyer	Immunological reagent and radioimmuno assay
US3867517A (en)	1971-12-21	1975-02-18	Abbott Lab	Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl)	1972-05-11	1983-06-01	Akzo Nv	Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en)	1973-03-12	1974-11-26	H Mcconnell	Process for assaying for biologically active molecules
US3876623A (en)	1973-05-09	1975-04-08	Lilly Co Eli	Process for purifying insulin
US3863008A (en)	1973-06-11	1975-01-28	American Home Prod	Somatostatin as stimulant of luteinizing hormone secretion
US3935074A (en)	1973-12-17	1976-01-27	Syva Company	Antibody steric hindrance immunoassay with two antibodies
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en)	1974-09-19	1977-07-05	The Board Of Trustees Of Leland Stanford Junior University	Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en)	1975-11-13	1976-10-05	General Electric Company	Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en)	1976-05-03	1977-07-19	The Massachusetts General Hospital	Composition and method for determining the size and location of myocardial infarcts
US4098876A (en)	1976-10-26	1978-07-04	Corning Glass Works	Reverse sandwich immunoassay
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en)	1980-09-19	1989-11-07	General Hospital Corporation	Immunoassay utilizing monoclonal high affinity IgM antibodies
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4476301A (en)	1982-04-29	1984-10-09	Centre National De La Recherche Scientifique	Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4687808A (en)	1982-08-12	1987-08-18	Biospecific Technologies, Inc.	Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
IL68218A (en)	1983-03-23	1985-12-31	Univ Ramot	Compositions for cartilage repair comprising embryonal chondrocytes
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5011771A (en)	1984-04-12	1991-04-30	The General Hospital Corporation	Multiepitopic immunometric assay
US5550111A (en)	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4666828A (en)	1984-08-15	1987-05-19	The General Hospital Corporation	Test for Huntington's disease
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en)	1985-03-15	1993-08-10	Anti-Gene Development Group	Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en)	1989-12-20	1995-04-11	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4801531A (en)	1985-04-17	1989-01-31	Biotechnology Research Partners, Ltd.	Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
WO1987000201A1 (en)	1985-07-05	1987-01-15	Whitehead Institute For Biomedical Research	Epithelial cells expressing foreign genetic material
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
GB8606913D0 (en)	1986-03-20	1986-04-23	Hider R C	Treatment of sickle cell disease
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0260032B1 (de)	1986-09-08	1994-01-26	Ajinomoto Co., Inc.	Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5166320A (en)	1987-04-22	1992-11-24	University Of Connecticut	Carrier system and method for the introduction of genes into mammalian cells
US4806484A (en)	1987-08-07	1989-02-21	Igb Products, Ltd.	Perfusion airlift bioreactor
EP0633318A1 (de)	1987-09-11	1995-01-11	Whitehead Institute For Biomedical Research	Transduktionsveränderte Fibroblasten und ihre Anwendung
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en)	1987-10-22	1993-02-23	Temple University Of The Commonwealth System Of Higher Education	Encapsulated 2',5'-phosphorothioate oligoadenylates
US5403711A (en)	1987-11-30	1995-04-04	University Of Iowa Research Foundation	Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
EP0348458B1 (de)	1987-11-30	1997-04-09	University Of Iowa Research Foundation	Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
WO1989005345A1 (en)	1987-12-11	1989-06-15	Whitehead Institute For Biomedical Research	Genetic modification of endothelial cells
WO1989007136A2 (en)	1988-02-05	1989-08-10	Whitehead Institute For Biomedical Research	Modified hepatocytes and uses therefor
JPH01222780A (ja)	1988-03-02	1989-09-06	Tosoh Corp	ウロキナーゼ前駆体様蛋白質のリフォールディング方法
WO1989009221A1 (en)	1988-03-25	1989-10-05	University Of Virginia Alumni Patents Foundation	Oligonucleotide n-alkylphosphoramidates
US5081035A (en)	1988-04-18	1992-01-14	The University Of Michigan	Bioreactor system
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5272057A (en)	1988-10-14	1993-12-21	Georgetown University	Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5256775A (en)	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
US5399493A (en)	1989-06-15	1995-03-21	The Regents Of The University Of Michigan	Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en)	1989-06-15	1995-08-01	Regents Of The University Of Michigan	Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5192659A (en)	1989-08-25	1993-03-09	Genetype Ag	Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US5264562A (en)	1989-10-24	1993-11-23	Gilead Sciences, Inc.	Oligonucleotide analogs with novel linkages
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5623065A (en)	1990-08-13	1997-04-22	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5149797A (en)	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en)	1990-02-15	1993-06-15	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of RNA and production of encoded polypeptides
US5321131A (en)	1990-03-08	1994-06-14	Hybridon, Inc.	Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
US5612211A (en)	1990-06-08	1997-03-18	New York University	Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US6326198B1 (en)	1990-06-14	2001-12-04	Regents Of The University Of Michigan	Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US5618704A (en)	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en)	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
ATE131827T1 (de)	1990-08-03	1996-01-15	Sterling Winthrop Inc	Verbindungen und verfahren zur unterdrückung der genexpression
US5177196A (en)	1990-08-16	1993-01-05	Microprobe Corporation	Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5214134A (en)	1990-09-12	1993-05-25	Sterling Winthrop Inc.	Process of linking nucleosides with a siloxane bridge
US5561225A (en)	1990-09-19	1996-10-01	Southern Research Institute	Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en)	1990-09-20	1995-01-18	Gilead Sciences Inc	Modified internucleoside linkages
DE69123981T3 (de)	1990-10-31	2006-06-14	Cell Genesys Inc	Nützliche retrovirale vektoren für die gentherapie
US5486359A (en)	1990-11-16	1996-01-23	Osiris Therapeutics, Inc.	Human mesenchymal stem cells
US5719262A (en)	1993-11-22	1998-02-17	Buchardt, Deceased; Ole	Peptide nucleic acids having amino acid side chains
US5714331A (en)	1991-05-24	1998-02-03	Buchardt, Deceased; Ole	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en)	1993-04-26	1996-07-23	Nielsen; Peter E.	Peptide nucleic acids
US5851832A (en)	1991-07-08	1998-12-22	Neurospheres, Ltd.	In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
CA2123094C (en)	1991-11-06	1999-08-10	Paulo N. Correa	Cell culture medium
US5700922A (en)	1991-12-24	1997-12-23	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
EP0629236B1 (de)	1992-03-04	2002-10-09	The Regents Of The University Of Michigan	Verfahren,zusammensetzungen und vorrichtungen zur erhaltung und zur züchtung menschlicher stammzellen und/oder hämatopoetischer zellen
US5792751A (en)	1992-04-13	1998-08-11	Baylor College Of Medicine	Tranformation of cells associated with fluid spaces
US5633360A (en)	1992-04-14	1997-05-27	Gilead Sciences, Inc.	Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en)	1992-06-01	1995-07-18	Gilead Sciences, Inc.	Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5281521A (en)	1992-07-20	1994-01-25	The Trustees Of The University Of Pennsylvania	Modified avidin-biotin technique
US5652355A (en)	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
US5320963A (en)	1992-11-25	1994-06-14	National Research Council Of Canada	Bioreactor for the perfusion culture of cells
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
EP0684828A4 (de)	1993-02-19	1996-08-07	Celtrix Pharma	Vermehrung von stammzellen in langzeitkulturen von knochenmarkzellen durch neutralisierung von t6f-beta.
US5654186A (en)	1993-02-26	1997-08-05	The Picower Institute For Medical Research	Blood-borne mesenchymal cells
GB9304618D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Chemical compounds
AU6412794A (en)	1993-03-31	1994-10-24	Sterling Winthrop Inc.	Oligonucleotides with amide linkages replacing phosphodiester linkages
US5342781A (en)	1993-07-15	1994-08-30	Su Wei Wen W	External-loop perfusion air-lift bioreactor
US5378725A (en)	1993-07-19	1995-01-03	The Arizona Board Of Regents	Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5830760A (en)	1993-07-28	1998-11-03	Fred Hutchinson Cancer Research Center	Creating novel hematopoietic cell lines by expressing altered retinoic acid receptors
US5504103A (en)	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
US5789543A (en)	1993-12-30	1998-08-04	President And Fellows Of Harvard College	Vertebrate embryonic pattern-inducing proteins and uses related thereto
US5599705A (en)	1993-11-16	1997-02-04	Cameron; Robert B.	In vitro method for producing differentiated universally compatible mature human blood cells
CA2178729A1 (en)	1993-12-09	1995-06-15	Eric B. Kmiec	Compounds and methods for site-directed mutations in eukaryotic cells
US6165747A (en)	1993-12-30	2000-12-26	President & Fellows Of Harvard College	Nucleic acids encoding hedgehog proteins
US6261786B1 (en)	1993-12-30	2001-07-17	Imperial Cancer Res. Technology	Screening assays for hedgehog agonists and antagonists
US6271363B1 (en)	1993-12-30	2001-08-07	President & Fellows Of Harvard College	Nucleic acids encoding hedgehog proteins
JPH09511392A (ja)	1994-02-09	1997-11-18	ユニシン・テクノロジーズ・インコーポレーテッド	高性能細胞培養バイオリアクターおよび方法
US5631219A (en)	1994-03-08	1997-05-20	Somatogen, Inc.	Method of stimulating hematopoiesis with hemoglobin
JPH09501324A (ja)	1994-03-11	1997-02-10	バクスター、インターナショナル、インコーポレイテッド	細胞保持用の溝を備えた貫流バイオリアクター
US5625050A (en)	1994-03-31	1997-04-29	Amgen Inc.	Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5489304A (en)	1994-04-19	1996-02-06	Brigham & Women's Hospital	Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft
US5480906A (en)	1994-07-01	1996-01-02	Eli Lilly And Company	Stereochemical Wortmannin derivatives
US5807718A (en)	1994-12-02	1998-09-15	The Scripps Research Institute	Enzymatic DNA molecules
US5770378A (en)	1994-12-30	1998-06-23	Ligand Pharmaceuticals, Inc.	Tricyclic retinoids, methods for their production and use
US5736396A (en)	1995-01-24	1998-04-07	Case Western Reserve University	Lineage-directed induction of human mesenchymal stem cell differentiation
US6077947A (en)	1995-02-02	2000-06-20	Cell Genesys, Inc.	DNA encoding an intracellular chimeric receptor comprising Janus kinase
US5716616A (en)	1995-03-28	1998-02-10	Thomas Jefferson University	Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en)	1995-04-21	1998-03-31	The Regent Of The University Of Michigan	Hematopoietic cells: compositions and methods
US5674750A (en)	1995-05-19	1997-10-07	T. Breeders	Continuous selective clonogenic expansion of relatively undifferentiated cells
US5925567A (en)	1995-05-19	1999-07-20	T. Breeders, Inc.	Selective expansion of target cell populations
US5712154A (en)	1995-06-07	1998-01-27	W.R. Grace & Co.-Conn.	Dual fiber bioreactor
US5728581A (en)	1995-06-07	1998-03-17	Systemix, Inc.	Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US6680166B1 (en)	1995-06-07	2004-01-20	Claudy Jean Paul Mullon	Dual fiber bioreactor
US6306575B1 (en)	1995-06-16	2001-10-23	Stemcell Technologies, Inc.	Methods for preparing enriched human hematopoietic cell preparations
JP3638958B2 (ja)	1995-07-28	2005-04-13	アプルス株式会社	ランセットの刺通深さを調節するためのアッセンブリ
US5652356A (en)	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
US6117850A (en)	1995-08-28	2000-09-12	The Collaborative Group, Ltd.	Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US6218128B1 (en)	1997-09-12	2001-04-17	Allergan Sales, Inc.	Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5952345A (en)	1995-09-01	1999-09-14	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6008204A (en)	1995-09-01	1999-12-28	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en)	1995-09-01	1998-07-07	Allergan, Inc.	Method of identifying negative hormone and/or antagonist activities
US5958954A (en)	1995-09-01	1999-09-28	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6329169B1 (en)	1995-09-29	2001-12-11	Human Genome Sciences, Inc.	Nucleic acid molecules encoding cytostatin II
FR2739777B1 (fr)	1995-10-11	1997-11-14	Cird Galderma	Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US6613565B1 (en)	1996-03-01	2003-09-02	Imclone Systems Incorporated	Use of delta-like protein to inhibit the differentiation of stem cells
US5877207A (en)	1996-03-11	1999-03-02	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
EP0891419A4 (de)	1996-03-12	2000-03-01	Life Technologies Inc	Nährstoffzusatz für hematopoetische zellkulturen
US6043092A (en)	1996-03-18	2000-03-28	University Of Pittsburgh	Cell culture media for mammalian cells
US5945309A (en)	1996-03-19	1999-08-31	Human Genome Sciences, Inc.	Cytostatin III nucleic acids encoding
TW442459B (en)	1996-04-15	2001-06-23	Hoffmann La Roche	Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
US6455678B1 (en)	1996-04-26	2002-09-24	Amcell Corporation	Human hematopoietic stem and progenitor cell antigen
CA2252524A1 (en)	1996-04-29	1997-11-06	Leuven Research & Development Vzw	Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits
US5851984A (en)	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
ES2196361T3 (es)	1996-08-28	2003-12-16	Inst Nat Sante Rech Med	Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
US5945337A (en)	1996-10-18	1999-08-31	Quality Biological, Inc.	Method for culturing CD34+ cells in a serum-free medium
JP2001505906A (ja)	1996-12-10	2001-05-08	ハダジットメディカルリサーチサービシズアンドディベラップメントカンパニーリミテッド	細胞の分化を誘導する血清由来因子およびその医薬的使用
US6335195B1 (en)	1997-01-28	2002-01-01	Maret Corporation	Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6294330B1 (en)	1997-01-31	2001-09-25	Odyssey Pharmaceuticals Inc.	Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (en)	1997-01-31	1998-07-31	Stephen William Watson Michnick	Protein fragment complementation assay for the detection of protein-protein interactions
US20030215445A1 (en)	1997-05-23	2003-11-20	Ginette Serrero	Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6372473B1 (en)	1997-05-28	2002-04-16	Human Genome Sciences, Inc.	Tissue plasminogen activator-like protease
CA2295474A1 (en)	1997-07-08	1999-01-21	Human Genome Sciences, Inc.	123 human secreted proteins
IT1293827B1 (it)	1997-08-07	1999-03-10	Dompe Spa	Metodo per l'espansione ex vivo di cellule staminali emopoietiche
US6440734B1 (en)	1998-09-25	2002-08-27	Cytomatrix, Llc	Methods and devices for the long-term culture of hematopoietic progenitor cells
FR2769491B1 (fr)	1997-10-15	2000-01-07	Patrick Sangouard	Sphincter artificiel reglable a commande magnetique
ES2270537T3 (es)	1997-11-12	2007-04-01	F. Hoffmann-La Roche Ag	Tratamiento de enfermedades inmunes mediadas por celulas t ayudantes de tipo 2.
US6248587B1 (en)	1997-11-26	2001-06-19	University Of Southern Cailfornia	Method for promoting mesenchymal stem and lineage-specific cell proliferation
ATE511752T1 (de)	1998-02-17	2011-06-15	Gamida Cell Ltd	Methode zur kontrolle der proliferation und differenzierung von stamm- und vorläuferzellen
US6962698B1 (en)	1998-02-17	2005-11-08	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
US6886568B2 (en)	1998-04-08	2005-05-03	The Johns Hopkins University	Method for fabricating cell-containing implants
US6413773B1 (en)	1998-06-01	2002-07-02	The Regents Of The University Of California	Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
WO1999064566A2 (en)	1998-06-08	1999-12-16	Osiris Therapeutics, Inc.	In vitro maintenance of hematopoietic stem cells
EP1084230B1 (de)	1998-06-08	2007-10-17	Osiris Therapeutics, Inc.	Regulierung der hämatopoietischen stammzelldifferenzierung durch verwendung von menschlichen mesenchymalen stammzellen
US6284540B1 (en)	1998-09-29	2001-09-04	Washington University	Artemin, a novel neurotrophic factor
JP2003523166A (ja)	1998-09-29	2003-08-05	ガミダセルリミテッド	幹細胞および前駆細胞の増殖と分化を制御する方法
US6667176B1 (en)	2000-01-11	2003-12-23	Geron Corporation	cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
CA2254429A1 (en)	1998-11-19	2000-05-19	Tully Michael Underhill	Compositions for promoting chondrogenesis
EP2314700A1 (de)	1999-01-28	2011-04-27	Medical College of Georgia Research Institute, Inc	Zusammensetzung und Verfahren zur in vivo und in vitro Abschwächung der Genexpression mittels dobbelsträngiger RNA
MXPA01007820A (es)	1999-02-04	2003-06-19	Technion Res & Dev Foundation	Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
DE19919242A1 (de)	1999-04-28	2000-11-02	Creavis Tech & Innovation Gmbh	Modulare Zellträgersysteme für dreidimensionales Zellwachstum
IL145941A (en)	1999-04-28	2007-08-19	Univ Texas	Compositions and methods for cancer treatment by selectively inhibiting vegf
AU4860900A (en)	1999-06-02	2000-12-18	Lifebank Services, L.L.C.	Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
US6652872B2 (en)	1999-07-06	2003-11-25	Ramat At Tel Aviv University Ltd.	Scaffold formed of tissue treated to eliminate cellular and cytosolic elements
US20020159984A1 (en)	1999-11-12	2002-10-31	Quality Biological, Inc.	Cultivation of cells for long term engraftment
US6541249B2 (en)	1999-12-22	2003-04-01	Human Genome Sciences, Inc.	Immortalized human stromal cell lines
US6303374B1 (en)	2000-01-18	2001-10-16	Isis Pharmaceuticals Inc.	Antisense modulation of caspase 3 expression
WO2001094549A2 (en)	2000-06-05	2001-12-13	The Burnham Institute	Methods of differentiating and protecting cells by modulating the p38/mef2 pathway
EP1315835A2 (de)	2000-08-01	2003-06-04	Yissum Research Development Company of the Hebrew University of Jerusalem	Gezielte differenzierung embryonaler zellen
US7198940B2 (en)	2000-10-25	2007-04-03	Shot Hardware Optimization Technology, Inc.	Bioreactor apparatus and cell culturing system
ES2171131B1 (es)	2000-11-10	2003-12-16	Idebio S L	Plaguicida biologico a base de quitosano
US6642019B1 (en)	2000-11-22	2003-11-04	Synthecan, Inc.	Vessel, preferably spherical or oblate spherical for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same
EP2316918B1 (de)	2001-02-14	2015-07-01	Anthrogenesis Corporation	Post-Partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
JP2004526449A (ja)	2001-03-29	2004-09-02	イクシオン・バイオテクノロジー・インコーポレーテッド	非膵性幹細胞の膵分化経路への分化転換法
KR100863624B1 (ko)	2001-05-11	2008-10-15	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
US20030017134A1 (en)	2001-06-19	2003-01-23	Technion Research And Development Foundation Ltd.	Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
DE10131388B4 (de)	2001-06-28	2004-07-08	Infineon Technologies Ag	Integrierter dynamischer Speicher und Verfahren zum Betrieb desselben
CA2351156A1 (en)	2001-07-04	2003-01-04	Peter W. Zandstra	A bioprocess for the generation of pluripotent cell derived cells and tissues
US20040235160A1 (en)	2001-08-07	2004-11-25	Mitsuo Nishikawa	Process for preparing hematopoietic stem cells
AU2002349912A1 (en)	2001-10-24	2003-05-06	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
US6887401B2 (en)	2001-11-05	2005-05-03	Essilor International Compagnie General D'optique	Method for making transparent polythiourethane substrates in particular optical substrates
AUPR892501A0 (en)	2001-11-16	2001-12-13	Peter Maccallum Cancer Institute, The	Method of enhancing self renewal of stem cells and uses thereof
US20050095228A1 (en)	2001-12-07	2005-05-05	Fraser John K.	Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7514075B2 (en)	2001-12-07	2009-04-07	Cytori Therapeutics, Inc.	Systems and methods for separating and concentrating adipose derived stem cells from tissue
DE10162814B4 (de)	2001-12-19	2005-06-23	Henkel Kgaa	Rekonstruiertes Haarfollikelmodell
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de)	2002-01-25	2006-06-07	Gamida Cell Ltd	Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
TWI314928B (en)	2002-02-28	2009-09-21	Novartis A	5-phenylthiazole derivatives and use as pi3 kinase inhibitors
JP2005520511A (ja)	2002-03-18	2005-07-14	ガミダセルリミテッド	エクスビボ拡大培養された幹細胞における分化を誘導する方法
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7247477B2 (en)	2002-04-16	2007-07-24	Technion Research & Development Foundation Ltd.	Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
BR0314402A (pt)	2002-08-19	2005-07-19	Gamida Cell Ltd	Expansão ex-vivo de populações de células raìzes em culturas celulares mononucleares
US20050054097A1 (en)	2002-11-17	2005-03-10	Tony Peled	EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US7470538B2 (en)	2002-12-05	2008-12-30	Case Western Reserve University	Cell-based therapies for ischemia
WO2004078917A2 (en)	2003-03-07	2004-09-16	Gamida-Cell Ltd.	Expansion of renewable stem cell populations using modulators of pi 3-kinase
US20040247574A1 (en)	2003-05-27	2004-12-09	Christopherson Kent W.	Methods for enhancing stem cell engraftment during transplantation
IL161903A0 (en)	2003-07-17	2005-11-20	Gamida Cell Ltd	Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
EP1649007A4 (de)	2003-07-17	2008-05-14	Gamida Cell Ltd	Verfahren zur ex-vivo-expansion von stamm-/ vorläuferzellen
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US20050260748A1 (en)	2004-02-27	2005-11-24	Michigan State University	Adult stem cells and uses thereof
WO2005086845A2 (en)	2004-03-10	2005-09-22	Regents Of The University Of California	Compositions and methods for growth of embryonic stem cells
EP1799812A4 (de)	2004-09-16	2009-09-09	Gamida Cell Ltd	Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
AU2005302291B2 (en)	2004-11-02	2011-02-10	The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services	Compositions and methods for treating hyperproliferative disorders
KR20070100908A (ko)	2005-01-31	2007-10-12	코그네이트 세러퓨틱 인크.	내피 세포의 특성을 나타내는 지방 유래 성인 스트로마세포
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
JP5102773B2 (ja)	2005-11-29	2012-12-19	ガミダセルリミテッド	幹細胞のホーミングおよび生着を改善する方法
US20100021434A1 (en)	2005-12-08	2010-01-28	Ramot At Tel Aviv University Ltd.	Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases
KR20090043559A (ko)	2006-08-15	2009-05-06	에이전시 포 사이언스, 테크놀로지 앤드 리서치	중간엽 줄기세포 조절배지
US20080199441A1 (en)	2006-11-09	2008-08-21	Tony Peled	Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
KR100995835B1 (ko) *	2007-12-18	2010-11-23	동국대학교 산학협력단	탯줄 유래의 중간엽 줄기세포를 이용한 간-특이기능이 있는간세포의 제조방법 및 이로부터 제조된 탯줄 유래 간세포
US20090257987A1 (en)	2008-04-10	2009-10-15	Ramot At Tel Aviv University Ltd.	Method of generating dopamine-secreting cells
US8062632B2 (en)	2008-06-23	2011-11-22	National Yang-Ming University	Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof
TWI397585B (zh)	2008-07-16	2013-06-01	Univ Nat Taiwan	細胞培養方法及其應用
GB0818725D0 (en)	2008-10-13	2008-11-19	Habib Nagy A	Pharmaceutical composition
PE20100362A1 (es)	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
JP5606008B2 (ja)	2009-04-13	2014-10-15	三菱重工業株式会社	骨髄間質細胞及び間葉系幹細胞の培養方法、中枢神経系疾患治療用の移植細胞の製造方法
EP2333047A1 (de)	2009-12-09	2011-06-15	Fresenius Medical Care Deutschland GmbH	Aus einer Erwachsenenstammzelle gewonnenes konditioniertes Medium und/oder Erwachsenenstammzellen zur Verwendung bei der therapeutischen Behandlung einer Tumorkrankheit
EP3184109B1 (de)	2009-12-29	2020-11-18	Gamida-Cell Ltd.	Methoden zur verstärkung des wachstums und der aktivierung von nk-zellen
WO2011139357A1 (en)	2010-05-03	2011-11-10	The Texas A & M University System	Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
EP2814951B1 (de)	2012-02-13	2019-04-03	Gamida-Cell Ltd.	Kultivierung mesenchymaler stammzellen
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells

2013
- 2013-02-13 EP EP13712603.3A patent/EP2814951B1/de active Active
- 2013-02-13 EP EP13711559.8A patent/EP2814950A1/de not_active Withdrawn
- 2013-02-13 US US14/378,235 patent/US10047345B2/en not_active Expired - Fee Related
- 2013-02-13 SG SG11201404608WA patent/SG11201404608WA/en unknown
- 2013-02-13 CN CN201380016363.8A patent/CN104204193B/zh not_active Expired - Fee Related
- 2013-02-13 WO PCT/IL2013/050137 patent/WO2013121427A1/en not_active Ceased
- 2013-02-13 HK HK15103074.6A patent/HK1202581A1/xx unknown
- 2013-02-13 IN IN1680MUN2014 patent/IN2014MN01680A/en unknown
- 2013-02-13 WO PCT/IL2013/050136 patent/WO2013121426A1/en not_active Ceased
- 2013-02-13 AU AU2013219945A patent/AU2013219945B2/en not_active Ceased
- 2013-02-13 CA CA 2863795 patent/CA2863795A1/en not_active Abandoned
- 2013-02-13 JP JP2014556198A patent/JP6348848B2/ja not_active Expired - Fee Related
- 2013-02-13 CN CN201380014921.7A patent/CN104204192A/zh active Pending
- 2013-02-13 US US14/378,221 patent/US20150064273A1/en not_active Abandoned
- 2013-02-13 BR BR112014020119-6A patent/BR112014020119A2/pt not_active Application Discontinuation
2014
- 2014-08-13 IL IL234095A patent/IL234095B/en active IP Right Grant
2017
- 2017-11-30 JP JP2017230030A patent/JP2018064572A/ja active Pending

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Seeliger C et al., "13th Annual Meeting on Surgical Research/13. Chirurgische Forschungstage 10.-12. September 2009, Hörsaaltrakt Klinikum Großhadern, Munich, Germany", Langenbecks Arch Surg, (2009-12-31), vol. 394, no. 5, pages 915 - 970 *

Also Published As

Publication number	Publication date
JP2015507921A (ja)	2015-03-16
CA2863795A1 (en)	2013-08-22
HK1202581A1 (en)	2015-10-02
CN104204192A (zh)	2014-12-10
US10047345B2 (en)	2018-08-14
BR112014020119A2 (pt)	2020-10-27
HK1199905A1 (en)	2015-07-24
IL234095B (en)	2018-06-28
WO2013121427A1 (en)	2013-08-22
EP2814950A1 (de)	2014-12-24
IL234095A0 (en)	2014-09-30
IN2014MN01680A (de)	2015-07-03
AU2013219945A1 (en)	2014-08-28
US20150004146A1 (en)	2015-01-01
EP2814951B1 (de)	2019-04-03
SG11201404608WA (en)	2014-09-26
CN104204193B (zh)	2016-10-26
WO2013121426A1 (en)	2013-08-22
US20150064273A1 (en)	2015-03-05
JP2018064572A (ja)	2018-04-26
EP2814951A1 (de)	2014-12-24
JP6348848B2 (ja)	2018-06-27
CN104204193A (zh)	2014-12-10

Publication	Publication Date	Title
AU2013219945B2 (en)	2017-12-07	Culturing of mesenchymal stem cells
JP4180228B2 (ja)	2008-11-12	脂肪組織由来の間質細胞に関する多様な中胚葉系統分化能およびその使用
Cheng et al.	2012	The influence of spheroid formation of human adipose-derived stem cells on chitosan films on stemness and differentiation capabilities
Braun et al.	2010	Evaluation of the osteogenic and chondrogenic differentiation capacities of equine adipose tissue-derived mesenchymal stem cells
Chong et al.	2012	Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells
Trivedi et al.	2008	Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells
JP5732011B2 (ja)	2015-06-10	非骨軟骨性の間葉組織由来の多能性細胞の同定および単離
Gottipamula et al.	2014	Isolation, expansion and characterization of bone marrow-derived mesenchymal stromal cells in serum-free conditions
Xiao et al.	2010	Clonal characterization of bone marrow derived stem cells and their application for bone regeneration
CA2645142C (en)	2015-01-13	Regulating stem cells
US20150329827A1 (en)	2015-11-19	Muse cells isolation and expansion
EP2537922B1 (de)	2021-04-21	Cd49f zur förderung der proliferation, multipotenz und neuprogrammierung von erwachsenenstammzellen durch pi3k/akt/gsk3-pfad
Baksh et al.	2007	A non‐contact suspension culture approach to the culture of osteogenic cells derived from a CD49elow subpopulation of human bone marrow‐derived cells
WO2021131261A1 (ja)	2021-07-01	細胞群及びその取得方法
US9982232B2 (en)	2018-05-29	Methods of generating cells with multilineage potential
WO2021227573A1 (zh)	2021-11-18	无异源培养基及使用其扩增间充质干细胞的方法
HK1199905B (en)	2018-01-05	Culturing of mesenchymal stem cells
Lanza et al.	2012	Immunosuppressive properties of mesenchymal stromal cells
Herrmann et al.	2016	Biological changes in human mesenchymal stromal cells during monolayer culture
Ferro	2013	Isolation, characterization and Ex-Vivo expansion of human synovial tissue derived-mesenchymal stem/stromal cells
PATRIKOSKI	0	Insights into the Use of Adipose Stem Cells for Clinical Cell Therapy
Pittenger	2011	Mesenchymal Stem Cells from Bone Marrow
IL193947A (en)	2013-08-29	Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it

Legal Events

Date	Code	Title	Description
2018-04-05	FGA	Letters patent sealed or granted (standard patent)
2020-09-10	MK14	Patent ceased section 143(a) (annual fees not paid) or expired